Metraipolis › archive › dc_740d5abcee07
FGF-23, hsCRP, Cardiovascular Events, and the Benefit of Canagliflozin in the CANVAS Trial — Europe PMC PMID:41151250
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41151250
- DOI
- 10.1016/j.jacadv.2025.102276
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T01:12:13.700Z
- SHA-256 of the archived text
2cf62527e5601603d7f91547b8abe896bf17a99ccb2fc28b8f4d10770e8c2b6f- Stable URL of this page
https://metraipolis.com/documento/dc_740d5abcee07
How to cite
FGF-23, hsCRP, Cardiovascular Events, and the Benefit of Canagliflozin in the CANVAS Trial — Europe PMC PMID:41151250 — Europe PMC (en), https://europepmc.org/article/MED/41151250 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_740d5abcee07 (Metraipolis archive dc_740d5abcee07, sha256 2cf62527e5601603d7f91547b8abe896bf17a99ccb2fc28b8f4d10770e8c2b6f)
BibTeX
@misc{dc740d5abcee07,
title = {FGF-23, hsCRP, Cardiovascular Events, and the Benefit of Canagliflozin in the CANVAS Trial — Europe PMC PMID:41151250},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41151250},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_740d5abcee07; sha256 2cf62527e5601603d7f91547b8abe896bf17a99ccb2fc28b8f4d10770e8c2b6f},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41151250. Agents can read the archived copy with the MCP tool read_document.